Teva Pharmaceutical Industries (TEVA) Total Current Liabilities (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Total Current Liabilities across 18 years of filings, most recently posting $13.5 billion for Q1 2026.

• Quarterly Total Current Liabilities rose 21.29% year-over-year to $13.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.5 billion (up 21.29% YoY) and the FY2025 annual result came in at $13.5 billion, up 5.16% from the prior year.
• Total Current Liabilities advanced to $13.5 billion in Q1 2026, from $13.5 billion in the prior quarter.
• Over five years, Total Current Liabilities peaked at $13.8 billion in Q3 2024 and troughed at $10.4 billion in Q1 2023.
• A 5-year average of $12.1 billion and a median of $11.8 billion in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Current Liabilities soared 32.48% — and 2025, when it dropped 19.11%.
• Tracing TEVA's Total Current Liabilities over 5 years: stood at $11.5 billion in 2022, then climbed by 6.78% to $12.2 billion in 2023, then grew by 4.48% to $12.8 billion in 2024, then gained by 5.16% to $13.5 billion in 2025, then grew by 0.56% to $13.5 billion in 2026.
• Business Quant data shows TEVA's Total Current Liabilities at $13.5 billion in Q1 2026, $13.5 billion in Q4 2025, and $11.5 billion in Q3 2025.